Andrew Hattersley outlines the findings from TriMaster, a randomized crossover trial demonstrating the potential of an individualized treatment approach for people with type 2 diabetes who require treatment intensification after first-line metformin (7:39).
00:00 Introduction and aims
01:55 Study population
03:07 Key results
05:56 Clinical implications